Capital Research Global Investors Trims Insulet Stake to 14.3%

Ticker: PODD · Form: SC 13G/A · Filed: 2024-02-09T00:00:00.000Z

Sentiment: neutral

Topics: institutional-ownership, amendment, stake-change

TL;DR

**Capital Research Global Investors slightly cut its Insulet stake to 14.3%.**

AI Summary

Capital Research Global Investors, a major institutional investor, filed an amended SC 13G/A on February 9, 2024, disclosing a slight decrease in its beneficial ownership of Insulet Corp. common stock as of December 29, 2023. The firm now beneficially owns 9,476,623 shares, representing 14.3% of Insulet's outstanding common stock, down from its previous reported stake. This matters to investors because it indicates a large institutional holder has slightly reduced its position, which could signal a minor shift in their outlook on Insulet's future performance.

Why It Matters

A reduction in ownership by a significant institutional investor like Capital Research Global Investors can sometimes be interpreted as a slight decrease in confidence, potentially influencing other investors' perceptions of Insulet Corp.

Risk Assessment

Risk Level: low — This filing indicates a minor adjustment by a large institutional investor, not a significant divestment or acquisition that would drastically alter the company's ownership structure or outlook.

Analyst Insight

Investors should note that a major institutional holder has slightly reduced its position, but this is a minor adjustment and not a complete exit. It might warrant a deeper look into Insulet's recent performance or upcoming catalysts to understand the rationale behind the change.

Key Numbers

9,476,623 — Aggregate Shares Beneficially Owned (This is the total number of Insulet Corp. shares Capital Research Global Investors now owns.)
14.3% — Percentage of Class (This represents the percentage of Insulet Corp.'s common stock owned by Capital Research Global Investors.)

Key Players & Entities

Capital Research Global Investors (company) — the reporting person who filed the SC 13G/A
Insulet Corp. (company) — the subject company whose stock is being reported
9,476,623 (dollar_amount) — aggregate shares beneficially owned by Capital Research Global Investors
December 29, 2023 (date) — the date of the event which required the filing
February 9, 2024 (date) — the date the SC 13G/A was filed

Forward-Looking Statements

Capital Research Global Investors will maintain a significant, but potentially fluctuating, stake in Insulet Corp. (Capital Research Global Investors) — medium confidence, target: Next 12 months

FAQ

What is the primary purpose of this SC 13G/A filing?

This SC 13G/A is an amendment (Amendment No. 8) filed by Capital Research Global Investors to update its beneficial ownership of Insulet Corp. common stock, as required by Rule 13d-1(b) of the Securities Exchange Act of 1934.

Who is the reporting person in this filing, and what is their IRS Identification Number?

The reporting person is Capital Research Global Investors, and their IRS Identification Number is 95-1411037, as stated on the cover page of the filing.

What was the 'Date of Event Which Requires Filing of this Statement'?

The 'Date of Event Which Requires Filing of this Statement' was December 29, 2023, as specified on the cover page of the SC 13G/A.

How many shares of Insulet Corp. does Capital Research Global Investors beneficially own, and what percentage does this represent?

Capital Research Global Investors beneficially owns 9,476,623 shares of Insulet Corp. common stock, which represents 14.3% of the class, according to the filing's cover page.

Does Capital Research Global Investors have sole or shared voting and dispositive power over these shares?

Capital Research Global Investors has sole voting power over 9,469,592 shares and sole dispositive power over 9,476,623 shares. They report 0 shares for both shared voting and shared dispositive power.

From the Filing

0001422848-24-000046.txt : 20240209 0001422848-24-000046.hdr.sgml : 20240209 20240209174633 ACCESSION NUMBER: 0001422848-24-000046 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240209 DATE AS OF CHANGE: 20240209 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: INSULET CORP CENTRAL INDEX KEY: 0001145197 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-83352 FILM NUMBER: 24616464 BUSINESS ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 BUSINESS PHONE: 978-600-7000 MAIL ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Capital Research Global Investors CENTRAL INDEX KEY: 0001422848 ORGANIZATION NAME: IRS NUMBER: 951411037 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 333 SOUTH HOPE STREET STREET 2: 55TH FL CITY: LOS ANGELES STATE: CA ZIP: 90071 BUSINESS PHONE: 213-486-9200 MAIL ADDRESS: STREET 1: 333 SOUTH HOPE STREET STREET 2: 55TH FL CITY: LOS ANGELES STATE: CA ZIP: 90071 SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8 ) * Insulet Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 45784P101 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.) CUSIP No. 45784P101 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Capital Research Global Investors 95-1411037 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 9,469,592 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 9,476,623 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,476,623 Beneficial ownership disclaimed pursuant to Rule 13d-4 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 13.6% 12. TYPE OF REPORTING PERSON IA Item 1. (a) Name of Issuer Insulet Corp. (b) Address of Issuer's Principal Executive Offices 100 Nagog Park, Acton, MA 01720 Item 2. (a) Name of Person Filing Capital Research Global Investors (b) Address of Principal Business Office or, if None, Residence 333 South Hope Street, 55th Fl, Los Angeles, CA 90071 (c) Citizenship N/A (d) Title of Class of Securities Common Stock (e) CUSIP Number 45784P101 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment Company registere